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Emergence of human immunoprofiling in health and disease  
ABSTRACT 
The human immune system is critical for 
maintaining health and providing protection from 
infectious diseases and cancer. Major advances in 
our understanding of the immune system have 
largely emerged from studies using animal models 
such as mice. However, this mouse-centric research 
has also limited our ability to comprehend the 
human immune system and how it changes with 
age and disease state. The fact that we have yet to 
define what constitutes a normal human immune 
system has hampered our ability to diagnose, treat, 
and prevent many human diseases. Immunoprofiling 
that measures the frequency of human immune 
cells based upon their functional biomarkers is 
critical for immunotherapy. With major advances 
in flow cytometry, mass cytometry, and imaging 
technology it is now possible to rapidly characterize 
many types of immune cells for immunotherapy 
and for monitoring disease. In this article, we 
discuss recent progress in immunoprofiling of the 
human immune system and how this system changes 
with age, chronic diseases, and autoimmunity. We 
also discuss this in the historical context as it 
relates to the emergence of human immunology. 
New knowledge generated by immunoprofiling 
studies will allow better understanding and 
monitoring of immune cells and their application 
in clinical medicine. 
KEYWORDS: biomarkers, human immunology, 
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The human immune system is a complex network 
of cells and proteins that are highly interactive, 
diverse, and adaptive. Humans have over 100 
immune cell types that are phenotypically highly 
stable within an individual but variable between 
individuals [1, 2]. This variability in frequency 
and functional responses of immune cells is due 
to genetic polymorphism and to the fact that the 
composition of the immune system is largely 
determined by non-genetic environmental factors, 
which can vary substantially from one individual 
to another [3]. Given its complex nature, it is 
difficult to define standard baseline values for the 
components of the normal immune system and 
how it changes with the long list of endogenous 
conditions (including genetics, sex, age, inflammation, 
microbiome and autoimmunity) and exogenous 
factors with which it interacts (such as infectious 
agents, diet, allergens, transplants and medications) 
[4-10].  
Immunoprofiling is a measure of the state of the 
immune system at a given time point. It provides 
a window into what immune cell types predict, 
induce, promote or prevent disease, and how the 
immune system responds to infections, vaccines, 
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or immunotherapy. As such, it contributes to our 
understanding of certain immunological baselines 
for it can be used to measure the impact of various 
therapies and the environmental influences on 
the immune system. Immunoprofiling of blood 
leukocytes provides a powerful tool for the 
monitoring of immune cells in vivo [11]. Monitoring 
of CD4+ T cell counts has been the hallmark of 
disease progression and therapy in HIV infected 
patients over the past three decades. What these 
activities have shown is that, in general, immune 
responses are driven by interactions between 
different immune cell types having stimulatory or 
suppressive proprieties. Immunoprofiling offers 
an opportunity to better understand these dynamic 
cellular interactions at a functional level. The 
development of immunoprofiling has been 
importantly powered by new technologies, such as 
flow cytometry, mass cytometry, cellular and 
molecular imaging, and the analysis of large data 
sets of genomics, proteomics and metabolomics 
studies that have added new understanding of the 
nature of immune cells. This has also contributed 
to a better tracking of pathogenic cells and 
immune cells in vivo and improved assessment of 
human immune function and clinical outcomes 
during immunotherapy [12, 13]. The area of 
human immunoprofiling is thus emerging from 
the recent developments in systems biology and 
human immunology [14]. It has provided new 
direction to the application of immunology in 
clinical medicine, the most noteworthy being 
cancer immunotherapy. This is likely to impact 
the discovery of new immunological mechanisms 
involving cell-cell interactions, cell signaling and 
the elucidation of genetic and environmental 
influences in human health. At the molecular 
level, immunoprofiling can be used to measure 
the diversity of immune responses based on 
antigen receptor specificity. Next generation 
sequencing of DNA allows profiling of antigen 
receptors on B cells and T cells and this can be 
used in turn to determine how the diversity of the 
receptors changes during immune response to 
antigens, allergens, infections, vaccines or transplants 
[15]. This has potential to develop genetic 
biomarkers for comparing baseline immune 
diversity and how it changes during disease or 
therapy. In cancer immunotherapy immunoprofiling 
is being used to develop biomarkers that can be 
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used to monitor treatments and detect remissions 
at an early stage. Therefore, immunoprofiling 
can be used at the molecular level to understand 
how immune cells target cancer cells and how 
immunotherapy helps in this process. 
While technological advancements provided new 
research opportunities, any discussion of the 
clinical application of immunoprofiling will be 
incomplete without the historical and philosophical 
context of the emergence of human immunology 
[12, 14, 16, 17]. In the last century, the discovery of 
the complex adaptive nature of the immune system 
helped to motivate a shift in perspective that raised 
a number of issues with research that focused 
overwhelmingly on animal models, particularly 
genetically modified inbred mouse models. 
Significant differences exist between the human 
immune system and that of experimental mouse 
models, which have limited the translation of 
these studies to humans. Because of this shift, the 
technological developments mentioned above, and 
the recent elucidation of the human genome, human 
immunology is now embracing new opportunities 
that may lead to the improved translation of 
research results into clinical outcomes. In this 
article we discuss the recent progress in the field 
of immune profiling and focus on the characterization 
of immune cells through immunophenotyping 
during the course of disease or in response to 
therapy. These studies will also help to define 
what constitutes a healthy or normal immune 
system, and serve as a clinical benchmark to 
assess immune changes with age, disease state 
and treatment. 
 
2. Human immunology – a developmental history
The field of human immunology has taken a leap 
forward in the past decade after being overshadowed 
by studies predominantly performed in mouse 
models of immunity over the past century. Both 
conceptual and technological advances have made 
this possible and we now have potential to better 
understand the immunological mechanisms and 
treatment of many human diseases given the 
genetic diversity and environmental influences in 
human populations.  
In the mid-18th century, immunology evolved as 
the study of mechanisms of protection against 












































Human immunoprofiling in health and disease 
background suggests that the immune system is a 
Complex Adaptive System (CAS) without an 
overall master regulator. It is not a simple aggregate 
of the properties of the immune systems’ components 
taken in isolation, but the result of complex and 
ongoing interactions between organisms and their 
environments. The immune system has emerged 
from the interactions among a large number of 
tightly integrated components in such a way as 
to enable the system to respond flexibly to a 
changing environment. In general, the immunity 
is modified in response to environmental stimuli 
of a different sort: the properties of certain kinds 
of molecules and antigens (e.g. vaccines) to which 
the organism is exposed via its immune receptors 
[19-21]. Ultimately, the primary selective pressure 
favouring the development of immunity is the 
need to resist infection [22].  
Accumulating evidence shows that the history of 
antigen exposure, including exposure to microbiota 
residing in or on body sites, systematically shapes 
the development and function of an individual’s 
immune system. Although immunological memory 
remains poorly understood at the cellular and 
molecular levels, some of its functional repercussions 
are well documented. We know for example that 
the immune system constantly builds a pool of 
memory lymphocytes based on microbial exposure 
and on immune interventions such as vaccines. 
Since the capacity of an organism to respond to 
pathogens depends on the repertoire of clones 
able to respond to antigens derived from those 
pathogens, the immune response depends on an 
individual's history of pathogen exposure. Thus, 
the physiology of an immune system depends 
not only on the present environment that it inhabits, 
but also on its history — both its individual 
developmental history and the evolutionary 
history of the population that it belongs to [23]. 
A further challenge to human immunology research 
results from the dynamic character of a CAS as 
it responds to a changing environment. The 
importance of both individual and evolutionary 
history of immune function implies primacy for 
the study of human immune systems in vivo.  
 
4. Normal human immune system  
In light of the immune system’s complex adaptive 
structure, it is important to develop conceptual 
development of inoculation and vaccination as 
measures for preventing smallpox. The realization 
that an infectious disease could be prevented by 
such methods inaugurated a program of research 
that culminated with the work of Louis Pasteur 
and the generation of vaccines for many infectious 
diseases including fowl cholera, anthrax, and 
rabies. This early research, with its close 
connection to clinical practice, was followed by 
a period of intense basic research along two 
different but complementary lines: cellular 
components and molecular units, both probing the 
mechanisms underlying immune function. Indeed, 
the recent interest in human immunology suggests 
that immunology is returning to its historical and 
clinical roots. 
For much of the last 50 years, immunology has 
focused on achieving a comprehensive mechanistic 
understanding of the molecular basis of immunity, 
aided by technological advances such as recombinant 
DNA and the application of molecular biology 
in developing and characterizing novel in vitro 
and in vivo models of immune function. Indeed, 
success in identifying molecular and cellular 
mechanisms of immunity has given immunology 
a high profile within medicine, offering potential 
mechanistic explanations for particular diseases 
and suggesting possibilities for therapeutic 
intervention and vaccine development. As a result, 
the discipline has grown beyond its descriptive 
focus of immunity [18] and now encompasses the 
study of disorders resulting from the loss of 
immune protection (e.g., primary and secondary 
immunodeficiency states), disorders associated 
with abnormal targeting of such mechanisms 
(e.g., allergy and autoimmune diseases), and 
therapeutic modulation of immune mechanisms 
(e.g., transplantation immunology and cancer 
immunotherapy). With this extended framework, 
immunology now reaches across disciplinary 
boundaries, demanding the integration of multiple 
disciplines including cell biology, biochemistry, 
anatomy, genetics, developmental biology, 
microbiology and infectious diseases, and 
epidemiology.  
 
3. Complexity of the human immune system 
Exploration of the conceptual landscape of 












































the common cold. Another implication of our 
definition is that one can discover different 
manifestations of immune system normality in a 
given context if there are diverse, yet adequate, 
responses to a given stimulus. 
 
5. Immunoprofiling and human health  
Immunoprofiling of cells in the normal immune 
system and their alteration during the course of 
disease progression or clinical treatment has 
become a cornerstone of immunotherapy. The 
selective use of biomarkers to simultaneously and 
rapidly measure distinct immune cell populations 
is critical for immunophenotyping and its 
application to disease monitoring and patient care 
[28, 29]. In this context we discuss the use of 
immunoprofiling in several health-related areas 
such as vaccination, aging, autoimmunity and 
chronic inflammatory diseases.  
5.1. Immunophenotypic readout of immune 
responses to vaccination 
In the last few years immune profiling has been 
successfully used in tracking immune responses in 
humans using systems biology approaches [17]. 
Using this approach, researchers have been able to 
identify early immune biomarkers that predict 
successful immune responses in humans vaccinated 
with the yellow fever vaccine [30], and provided 
correlates of successful vaccination with over 
90% accuracy, thus measuring early vaccine 
efficiency. These studies have pointed to the 
development of rapid tests for determining whether a 
person can respond effectively to a vaccine and 
define the utility of phenotyping of immune cells 
in predicting vaccine efficacy [31, 32]. 
5.2. Age-related immunophenotypic changes 
It is known that aging humans undergo dramatic 
changes in their immune system along with an 
increased susceptibility to infections and chronic 
diseases including cancer. Conventional approaches 
have identified several underlying factors such as 
reduced CD8+ T cells and impaired dendritic cell 
function in the elderly. Similar changes are 
observed in patients with chronic diseases and 
cancer. However, given the diversity of the human 
population it is necessary to develop more 
universally applicable biomarkers that can be used 
to monitor the immune system and correlate to
 
 
and investigative tools for studying the dynamic 
nature of the intact human immune system in its 
natural environment. In this context immunoprofiling 
offers a valuable tool to define the normal and an 
altered immune system and what “normal” should 
mean in the context of an immune system [16]. As 
Georges Canguilhem argued [24], the concepts of 
normality and pathology are essential to medicine 
and can be comprehended only in its context. The 
task of defining normality in a system such as the 
immune system is particularly challenging given 
its dynamic nature and the biological, social and 
environmental factors that may alter the status of 
an apparently normal or otherwise “healthy” immune 
system. Yet providing a precise specification of 
the normal immune system is an important step 
towards the definition of immune health determinants. 
We need to understand two basic questions about 
the human immune system. First, what is a normal 
human immune system and how does it develop 
and decline with age? Second, how do disease 
states impact the immune system? Answer to 
these questions are prolegomena to expanding the 
horizon of the human immunology research and 
enhancing its impact on medical practice [25-27].  
We believe that this can be done in a way 
analogous to the identification of individual and 
social risk factors. The complex adaptive structure 
of the immune system implies that what counts as 
normal will change from one environment to 
another, and indeed from one life-history to 
another even within the same environment. Thus, 
multiple alternative normal states for the immune 
system may be possible, depending on the 
environments (natural and cultural) in which it 
develops. In light of this historical and context 
sensitivity, we define a normal immune system as 
one that provides adequate immunity for a specific 
environment. This definition has important 
empirical and clinical ramifications. If we accept 
that what is “normal” should be determined by 
what is “adequate for the organism’s health”, then 
the induction of immune responses by vaccination 
or the presence of ongoing immune responses to 
environmental antigens or certain microbes should 
be viewed as compatible with normality. Our 
definition encompasses exposure to pathogens as 
a requirement for normal development of the 
immune system or to build normal immunity to 
minor frequent infections such as chickenpox and










































Human immunoprofiling in health and disease 
Although age-related changes in DNA methylation 
is a good predictor of overall mortality, recent 
studies [34] suggest that IMM-AGE score can 
predict mortality in older adults better than 
epigenetic clock data or chronological age. Using 
immunophenotyping the authors found changes in 
immune cells from their baseline values over a 
9-year period in 135 subjects selected from the 
Framingham Heart studies [35]. These studies 
suggest that in older adults, the immune systems 
change over time and the IMM-AGE score can 
predict overall survival independent of age, gender, 
and cardiovascular diseases [34].  
5.3. Immunophenotyping in cancer therapy  
Immune cells are known to infiltrate tumors and 
there is good evidence that immunoprofiling can 
be used to predict a patient’s anti-tumor response 
in cancer therapy [36]. Tumor infiltrating immune 
cells represent an important determinant of clinical 
responses in immunotherapy. The monitoring of 
anti-tumor immune responses by immunoprofiling 
during treatment with checkpoint inhibitor drugs 
such as anti-CTLA-4 and anti-PD-1 antibodies 
has become an essential tool in immunotherapy 
[37, 38]. This is important because only about 
20%-30% cancer patients respond to checkpoint 
immunotherapy [37] and in some cases, it may 
even promote tumor growth [39]. Therefore, 
immunoprofiling of immune cells may be critical 
to determine their efficacy in cancer immunotherapy.
5.4. Immunophenotyping in autoimmune diseases 
Autoimmune diseases are caused by the cells of 
the immune system. Monitoring and treating 
these diseases require a clear understanding of the 
type and function of immune cells involved in a 
particular disease. Significant progress has been 
made to determine the involvement of various 
immune cells in autoimmune diseases such as 
diabetes, lupus, arthritis, inflammatory bowel 
disease and multiple sclerosis [40]. However, the 
use of immunotherapy in autoimmune diseases 
remains a major challenge in clinical medicine 
due to the paucity of effective treatments to 
inhibit or regulate autoreactive effector immune 
cells in the disease process. Immunoprofiling of 
these cells is likely to facilitate development of 
new immunotherapies for autoimmune diseases. 
The use of biomarkers to define these immune 
cells has also become an important diagnostic step
  
 
disease risk. Immunoprofiling thus becomes an 
important platform for monitoring the age-related 
changes that occur in the human immune system 
[33]. Immunoprofiling done over 9 years in a 
human cohort gave an immune aging (IMM-AGE) 
score based on 33 cellular subsets, including 
CD8+ T cell, monocytes, natural killer (NK) cells, 
B cells, and CD4+ T cell subsets. [34]. This score, 
which enables tracking immune age in real time, 
was related to genetics, environmental and previous 
exposure to pathogens. Similarly, individual cytokine 
response was more significantly associated with 
the IMM-AGE score than with actual age of the 
subjects. This study suggests that the immune 
cell variation between individuals was greater 
than that within an individual over time. The 
high inter-individual immune cell variability is 
dependent on their baseline value. Moreover, 
there was significant immune-system dynamics in 
older subjects as compared to its stability in the 
younger subjects. It appears that immune cell 
homeostasis of young and older adults differs but 
over time they converge and move towards the 
adult phenotype as defined by an increased pool 
of memory lymphocytes with age [34].  
5.2.1. Cardiovascular diseases and 
immunophenotyping changes 
Recently Alpert et al. [34] explored a link 
between inflammation and cardiovascular disease 
using immunoprofiling. This is a powerful example 
of the application of immunoprofiling to monitor 
chronic diseases that develop with age [34]. For 
this study, the authors explored the IMM-AGE 
score in the famous Framingham Heart Study 
cohort [35] and found that this score was strongly 
associated with cardiovascular disease. Therefore, 
IMM-AGE score can be used as a risk factor for 
the development of cardiovascular disease and 
appropriate subjects could therefore be potentially 
enrolled in clinical trials based upon their IMM-
AGE score. Thus, immunoprofiling could serve as 
a useful tool in chronic disease prevention studies. 
There is a need to expand these studies to other 
chronic human diseases as well as in animal 
models to confirm their validity.  
5.2.2. Age related mortality and 
immunophenotyping changes 
Aging alters most physiological responses in a 
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blood mononuclear cells using flow cytometry. 
They found that the frequency of memory 
CXCR4+CD4+ T cells is linked to the expression 
of HLA-DR on B cells. Moreover, memory 
CXCR4+CD4+ T cells serves as an important 
biomarker for linkage between HLA-DRB1 
genotype and disease activity in RA. 
Immunophenotyping has also revealed that patients 
with systemic lupus erythematosus (SLE or lupus) 
can be classified into three subgroups based on 
the heterogeneity of T cells involved in the 
disease [49]. The level of Treg and follicular 
helper T (Tfh) cells were higher in SLE patients 
than in healthy controls. Cluster analysis from this 
study has shown that patients whose SLE was 
resistant to treatment was highest among the Tfh-
dominant group.  
Immunotherapy of multiple sclerosis (MS) has 
been monitored by immunoprofiling of immune 
cells in patients treated with interferon-β (IFN-β) 
and fingolimod. The study revealed significant 
alterations in their B cell subsets and an increase 
in B cell-activating factor (BAFF) following 
therapy [50]. This was unexpected as previous 
studies primarily focused on the role of T cells 
and not on B cells in MS [51]. Similar results 
were obtained in MS patients treated with anti-
CD20 monoclonal antibodies that targeted B cells 
and modulated disease [52]. 
In Inflammatory Bowel Disease (IBD), a disease 
in which gut microbiota plays an important role, 
there appears to be a strong link between T cell 
subsets and disease induction as determined by 
immune profiling of T cells in the intestine [53, 
54]. This study explored changes in intestinal 
T cells and found increased level of CD4+ T cells, 
Tregs, and resident memory T (TRM) cells, and 
lower levels of CD8+ T cells and CD103+ T cells 
in patients compared to the controls. This suggests 
that the baseline level of CD4+ Treg cells in 
IBD patients was strongly associated with IBD 
progression. 
 
6. Significance of immunoprofiling data in 
health and disease management  
The immune system impacts almost every disease 
in humans and immunophenotyping has potential 
to characterize individual’s immune health by 
analysing the number of different types of 
in the classification and monitoring of the clinical 
course of an autoimmune disease [41, 42]. Use of 
immunophenotyping to monitor various mononuclear 
cell subsets, including memory B cells, effector 
T cells, and dendritic cells in autoimmune disease 
is likely to become a precision medicine tool in 
the diagnosis and follow-up of patients with 
autoimmune diseases. 
Type 1 diabetes (T1D) is characterized by a change 
in the frequency and phenotype of immune cells 
during the development of the disease [43]. This 
is associated with humoral immune responses to 
islet b-cell autoantigens—particularly insulin, 
glutamic acid decarboxylase (GAD), islet antigen-2 
(IA-2), and zinc transporter 8 (ZnT8). The titer of 
autoantibodies to these antigens in T1D increases 
with time. The immunophenotyping in this case is 
characterized by a more intense humoral autoimmune 
response to islet autoantigens. Patients with T1D 
also exhibited multiple immunophenotypic 
abnormalities in circulating B cells compared to 
healthy controls [44]. This is associated with 
decreased percentages of Fas receptor- positive 
mature B cells. Immunophenotypic analysis has 
shown that both CD4 and CD8 T cells are 
involved in T1D. These cells are kept in check by 
regulatory T (Treg) cells whose diminished Treg 
cell function appears to be involved in T1D 
development [45, 46]. It is, therefore, going to be 
critical to monitor the frequency of Treg cells in 
T1D patients using immunoprofiling in patients. 
The role of dendritic cells is also important in 
T1D as they influence the activation and function 
of T cells that are involved in the induction and 
progression of disease. In our studies [47], 
immunoprofiling of dendritic cells was done using 
4-color flow cytometry of whole blood cells from 
type 1 and type 2 diabetic patients and control 
subjects. It was found that dendritic cell frequency 
in the diabetic state did not differ from 
nondiabetic control subjects but they were poor 
producers of IFN-α which may influence disease 
development. 
Rheumatoid arthritis (RA) is a chronic autoimmune 
disease. In this disease, immunophenotyping has 
revealed a link between HLA-DRB1 and CXCR4 
expression on memory CD4+ T cells that are 
involved in the disease process [48]. In this study, 
the authors analyzed HLA-DRB1+ RA patients 











































Human immunoprofiling in health and disease 
ongoing interaction with the environment. Recent 
immunoprofiling studies outlined above have 
provide fascinating new insight into the human 
immune system and its promising role in health 
and disease. It is imperative to translate new basic 
biomedical research findings relating to the 
human immune system into clinical applications 
and outcomes. We demonstrated in this review 
that immunoprofiling offers an important new 
platform for analyzing immune cells in the 
evolution of human immunology as it emerges 
from the shadows of mouse centric studies [16]. 
Immunoprofiling studies outlined above point to 
the new opportunities that the area of human 
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